Assessing the Emergence of Resistance: The Absence of Biological Cost In Vivo May Compromise Fosfomycin Treatments for P. aeruginosa Infections

Alexandro Rodríguez-Rojas, María D. Maciá, Alejandro Couce et al. · 2010

Read Assessing the Emergence of Resistance: The Absence of Biological Cost In Vivo May Compromise Fosfomycin Treatments for P. aeruginosa Infections by Alexandro Rodríguez-Rojas, María D. Maciá, Alejandro Couce et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0010193.txt.

Description

The authors were Alexandro Rodríguez-Rojas, María Maciá, Alejandro Couce, and others. Their 2010 PLOS ONE study looked at drug resistance in a tough germ. The drug fosfomycin treats simple bladder and gut infections well. Mutants that resist it arise often in lab tests, but they were thought to pay a high cost for that trait.

The team checked how resistance emerges and what it costs in living hosts. Their concern was plain: if there is no cost in the body, resistant germs can persist. That would weaken a useful drug against infections caused by Pseudomonas aeruginosa.

Catalog record

CREATORAlexandro Rodríguez-Rojas, María D. Maciá, Alejandro Couce et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0010193

Browse the full library · About the Tower of Babel